enGene Therapeutics (ENGN) Notes Payables (2022 - 2026)
enGene Therapeutics (ENGN) posted quarterly Notes Payables of $193000.0 for Q2 2026, down 94.59% year-over-year from $3.6 million in Q2 2025, and up 2.66% quarter-over-quarter from $188000.0 in Q1 2026.
enGene Therapeutics (ENGN) Notes Payables (2022 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Notes Payables for 5 consecutive years, with $193000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Notes Payables fell 94.59% year-over-year to $193000.0; the TTM figure through Apr 2026 stood at $193000.0 (down 94.59% YoY), while the FY2025 annual figure was $8.0 million, up 1044.78% from the prior year.
- Notes Payables grew to $193000.0 in Q2 2026 per ENGN's latest filing, from $188000.0 in the prior quarter.
- Across five years, Notes Payables topped out at $40.0 million in Q3 2023 and bottomed at $188000.0 in Q1 2026.
- Historically, Notes Payables has averaged $5.7 million across 5 years, with a median of $1.3 million in 2024.
- Annual changes were most pronounced in 2024 — Notes Payables slumped 96.65% — and 2025, when it surged 1044.78%.
- enGene Therapeutics' Notes Payables stood at $1.3 million in 2022, then plunged by 55.57% to $562000.0 in 2023, then rose by 24.38% to $699000.0 in 2024, then soared by 1044.78% to $8.0 million in 2025, then slumped by 97.59% to $193000.0 in 2026.
- Business Quant data shows ENGN's Notes Payables at $193000.0 in Q2 2026, $188000.0 in Q1 2026, and $8.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - |
| 10 | enGene Therapeutics | 123.41 Mn | 123.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 193,000.00 |
| Jan 31, 2026 | 188,000.00 |
| Oct 31, 2025 | 8.00 Mn |
| Jul 31, 2025 | 5.41 Mn |
| Apr 30, 2025 | 3.57 Mn |
| Jan 31, 2025 | 1.69 Mn |
| Oct 31, 2024 | 699,000.00 |
| Jul 31, 2024 | 1.34 Mn |
| Oct 31, 2023 | 562,000.00 |
| Jul 31, 2023 | 39.99 Mn |
| Oct 31, 2022 | 1.27 Mn |